Effect of Tirofiban combined with thrombolytic therapy of Reteplase on the changes of cardiac parameters, levels of serum factors in elderly patients with ST-elevation myocardial infarction
GUO Jiaru GUO Shougui
Department of Cadre Ward, PLA 175th Hospital the Affiliated Dongnan Hospital of Xiamen University, Fujian Province, Zhangzhou 363000, China
Abstract:Objective To discuss the effects of Tirofiban combined with thrombolytic therapy of Reteplase on the changes of cardiac parameters, levels of serum factors in elderly patients with ST-elevation myocardial infarction. Methods One hundred and six cases of elderly patients with ST-elevation myocardial infarction treated in PLA 175th Hospital from December 2013 to March 2016 were selected and divided into study group and control group according to the random digital table method, with 53 patients in each group. The control group was given thrombolytic therapy of Reteplase, while the study group was given Tirofiban combined with thrombolytic therapy of Reteplase. The changes of cardiac parameters such as left ventricular end systolic diameter (LVESD), left ventricular diastolic end diastolic diameter (LVEDD), left ventricular shoot ejection fraction (LVEF), stroke volume (SV) in the two groups were observed, as well as the serum high sensitive C reactive protein (hs-CRP), homocysteine (Hcy) and complement 3 (C3) levels and the incidence rate of complications. Results There were no significant differences in the levels of SV, LVEDD, LVESD and LVEF between the two groups before treatment (P > 0.05). The LVEDD and LVESD in the two groups after treatment were significantly decreased compared with those before treatment, which in the study group after treatment were significantly lower than those in the control group (P < 0.05). The levels of SV and LVEF in the two groups after treatment were significantly increased compared with those before treatment (P < 0.05), which in the study group after treatment were significantly higher than those in the control group (P < 0.05). There were no significant differences in the levels of hs-CRP, Hcy, and C3 between the two groups before treatment (P > 0.05). The levels of hs-CRP, Hcy, C3 in the two groups after treatment were significantly decreased compared with those before treatment, which in the study group were significantly lower than those in the control group (P < 0.05). The incidence rate of complications in the study group was 9.43%, which was significantly lower than that in the control group (43.40%) (P < 0.05). Conclusion The application of Tirofiban combined with thrombolytic therapy of Reteplase can effectively improve the heart function, decrease the levels of hs-CRP, Hcy, C3 and reduce complications.
郭佳茹 郭寿贵. 替罗非班联合瑞替普酶溶栓对老年ST段抬高型心肌梗死患者心功能指标变化、血清因子水平的影响[J]. 中国医药导报, 2017, 14(14): 119-122.
GUO Jiaru GUO Shougui. Effect of Tirofiban combined with thrombolytic therapy of Reteplase on the changes of cardiac parameters, levels of serum factors in elderly patients with ST-elevation myocardial infarction. 中国医药导报, 2017, 14(14): 119-122.